{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:40:20Z","timestamp":1791819620714,"version":"4.3.4"},"reference-count":46,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,12,14]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"\n Objective<\/jats:title>\n To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Safety data from clinical trials of upadacitinib 15\u2009mg and upadacitinib 30\u2009mg (AD only) for treating RA, PsA, AS and AD as of 30 June 2021 were analysed; some RA and PsA studies included adalimumab and methotrexate as active comparators. Treatment-emergent adverse events (TEAEs) were presented by disease as exposure-adjusted event rates per 100 patient years (E\/100 PY).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The analysis included 6991 patients (RA, n=3209; PsA, n=907; AS, n=182; AD, n=2693) who received at least one dose of upadacitinib, representing 15 425 PY of exposure (maximum duration 2.75\u20135.45 years) across diseases. Rates (E\/100 PY) of any TEAE (205.5\u2013278.1) and TEAE leading to discontinuation (4.5\u20135.4) were similar across diseases; serious TEAEs were numerically higher in patients with RA and PsA. Rates of herpes zoster (1.6\u20133.6), non-melanoma skin cancer (0\u20130.8) and elevations in creatine phosphokinase levels (4.4\u20137.9) were higher with upadacitinib than with active comparators in the RA and PsA populations. Deaths (0\u20130.8), serious infections (0\u20133.9), major adverse cardiovascular events (0\u20130.4), venous thromboembolism (<0.1\u20130.4) and malignancies (0.3\u20131.4) were observed, with rates generally lowest in AS and AD. Increased rates of acne were observed in patients with AD only.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Findings from this analysis demonstrate that upadacitinib is generally well tolerated with observed differences in safety profiles likely reflective of varying patient characteristics across RA, PsA, AS and AD populations.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n NCT02675426<\/jats:ext-link>, NCT02706951<\/jats:ext-link>, NCT02706847<\/jats:ext-link>, NCT02629159<\/jats:ext-link>, NCT02706873<\/jats:ext-link>, NCT03086343<\/jats:ext-link>, NCT03104374<\/jats:ext-link>, NCT03104400<\/jats:ext-link>, NCT03178487<\/jats:ext-link>, NCT03569293<\/jats:ext-link>, NCT03568318<\/jats:ext-link> and NCT03607422<\/jats:ext-link>.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002735","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T10:25:48Z","timestamp":1675851948000},"page":"e002735","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":208,"title":["Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02675426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706873","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03086343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03104374","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03104400","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03178487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03569293","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03568318","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03607422","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-979X","authenticated-orcid":false,"given":"Stanley B","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Metroplex Clinical Research Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University School of Medicine, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Irvine","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland"},{"name":"Wellcome-HRB Clinical Research Facility, St. James' Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Rheumatology, Organizaci\u00f3n Medica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P","family":"Lacerda","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Palac","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Shaw","sequence":"additional","affiliation":[{"name":"AbbVie Ltd, Maidenhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research Division, Swedish Medical Center\/Providence St. Joseph Health, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman\u2011Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"2025090313164151000_9.1.e002735.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00603-1"},{"key":"2025090313164151000_9.1.e002735.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"2025090313164151000_9.1.e002735.3","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72 Suppl 2","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025090313164151000_9.1.e002735.4","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. new players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"2025090313164151000_9.1.e002735.5","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology"},{"key":"2025090313164151000_9.1.e002735.6","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"2025090313164151000_9.1.e002735.7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"2025090313164151000_9.1.e002735.8","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090313164151000_9.1.e002735.9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236"},{"key":"2025090313164151000_9.1.e002735.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090313164151000_9.1.e002735.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2025090313164151000_9.1.e002735.12","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313164151000_9.1.e002735.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2025090313164151000_9.1.e002735.14","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"2025090313164151000_9.1.e002735.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2025090313164151000_9.1.e002735.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"2025090313164151000_9.1.e002735.17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2025090313164151000_9.1.e002735.18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"2025090313164151000_9.1.e002735.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2025090313164151000_9.1.e002735.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"2025090313164151000_9.1.e002735.21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (select-early): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090313164151000_9.1.e002735.22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2025090313164151000_9.1.e002735.23","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2147\/DDDT.S340459","article-title":"Evaluating upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: design, development, and potential position in therapy","volume":"16","author":"Napolitano","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2025090313164151000_9.1.e002735.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2025090313164151000_9.1.e002735.25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials","volume":"9","author":"Burmester","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090313164151000_9.1.e002735.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"van der Heijde","year":"2022","journal-title":"RMD Open"},{"key":"2025090313164151000_9.1.e002735.27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","article-title":"Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials","volume":"87","author":"Mendes-Bastos","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025090313164151000_9.1.e002735.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"2025090313164151000_9.1.e002735.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776"},{"key":"2025090313164151000_9.1.e002735.30","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514059"},{"key":"2025090313164151000_9.1.e002735.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"2025090313164151000_9.1.e002735.32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/ijd.15853","article-title":"Safety of janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis","volume":"61","author":"Wood","year":"2022","journal-title":"Int J Dermatol"},{"key":"2025090313164151000_9.1.e002735.33","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"key":"2025090313164151000_9.1.e002735.34","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313164151000_9.1.e002735.35","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313164151000_9.1.e002735.36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090313164151000_9.1.e002735.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2025090313164151000_9.1.e002735.38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090313164151000_9.1.e002735.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-02325-9","article-title":"Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"2025090313164151000_9.1.e002735.40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.therap.2022.04.005","article-title":"Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis","volume":"77","author":"Jalles","year":"2022","journal-title":"Therapie"},{"key":"2025090313164151000_9.1.e002735.41","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1111\/all.14853","article-title":"Eczema herpeticum in atopic dermatitis","volume":"76","author":"Traidl","year":"2021","journal-title":"Allergy"},{"key":"2025090313164151000_9.1.e002735.42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313164151000_9.1.e002735.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203380"},{"key":"2025090313164151000_9.1.e002735.44","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001392"},{"key":"2025090313164151000_9.1.e002735.45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa262"},{"key":"2025090313164151000_9.1.e002735.46","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11741"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:16:53Z","timestamp":1756930613000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,8]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/rmdopen-2022-002735"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002735","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}